Table 1. Patient characteristics and... | American Society of Hematology

Table 1.

Patient characteristics and immune reconstitution of study group

Characteristic	All patients (n = 14)	Patients with HSV (n = 7)	Patients without HSV (n = 7)
Median age, y (range)	31.5 (21-56)	39 (21-47)	28 (23-56)
Male/female	12/2	6/1	6/1
Diagnosis
Acute leukemia	10	5	5
CML (chronic phase 2)	2	1	1
NHL/myelofibrosis	2	1	1
HSV-1/-2 seropositive	9/6	7/5	2/1^*
CMV seropositive	5	4	1
GVHD grades II-IV	3	2	1
Median time to ANC > 500/mm³(range)	11 d (9-27)	11 d (9-27)	13 d (9-18)
Median CD4⁺ count: 45 d; 100 d; 6 mo after transplant (cells/mm³)	2/mm³; 3/mm³; 55/mm³	4/mm³; 3/mm³; 93/mm³	0/mm³; 61/mm³; 55/mm³
Median CD8⁺count: 45 d; 100 d; 6 mo after transplant (cells/mm³)	0/mm³; 2/mm³; 29/mm³	19/mm³; 2/mm³; 68/mm³	0/mm³; 38/mm³; 29/mm³
Median CD56⁺ count: 45 d; 100 d; 6 mo after transplant (cells/mm³)	266/mm³; 164/mm³; 321/mm³	266/mm³; 164/mm³; 265/mm³	266/mm³; 169/mm³; 321/mm³

Characteristic	All patients (n = 14)	Patients with HSV (n = 7)	Patients without HSV (n = 7)
Median age, y (range)	31.5 (21-56)	39 (21-47)	28 (23-56)
Male/female	12/2	6/1	6/1
Diagnosis
Acute leukemia	10	5	5
CML (chronic phase 2)	2	1	1
NHL/myelofibrosis	2	1	1
HSV-1/-2 seropositive	9/6	7/5	2/1^*
CMV seropositive	5	4	1
GVHD grades II-IV	3	2	1
Median time to ANC > 500/mm³(range)	11 d (9-27)	11 d (9-27)	13 d (9-18)
Median CD4⁺ count: 45 d; 100 d; 6 mo after transplant (cells/mm³)	2/mm³; 3/mm³; 55/mm³	4/mm³; 3/mm³; 93/mm³	0/mm³; 61/mm³; 55/mm³
Median CD8⁺count: 45 d; 100 d; 6 mo after transplant (cells/mm³)	0/mm³; 2/mm³; 29/mm³	19/mm³; 2/mm³; 68/mm³	0/mm³; 38/mm³; 29/mm³
Median CD56⁺ count: 45 d; 100 d; 6 mo after transplant (cells/mm³)	266/mm³; 164/mm³; 321/mm³	266/mm³; 164/mm³; 265/mm³	266/mm³; 169/mm³; 321/mm³

CML indicates chronic myelogenous leukemia; NHL, non-Hodgkin lymphoma; GVHD, graft-versus-host disease.

Two patients (with pretransplant HSV-1/HSV-2 serologies +/+ and +/−) died on days 6 and 8 after transplantation, respectively.